

Invasive and Non-Invasive Osteomyelitis Caused by Group B Streptococcus Infection Among Veterans

Taissa Bej, MS¹; Brigid Wilson, PhD^{1,2}; Richard Banks, BS¹; Janet Briggs, RN, MSN, NP¹;
 Sunah Song, MPH²; Robin L Jump, MD, PhD^{1,2}; Federico Perez, MD, MSc^{1,2}

¹VA Northeast Ohio Healthcare System, Cleveland, Ohio; ²Case Western Reserve University, Cleveland, Ohio



Background

- Rates of invasive infections caused by Group B Streptococcus (GBS) are increasing among adults¹
- Epidemiological studies that assess invasive Group B Streptococcus (GBS) infections may not capture cases of osteomyelitis diagnosed using non-invasive cultures in combination with imaging, laboratory tests, and clinical assessment.

Objective

- To assess the incidence and compare outcomes among individuals diagnosed with GBS osteomyelitis using invasive and non-invasive cultures.

Methods

- We used the US Veterans Health Administration (VHA) database to identify a retrospective cohort of patients diagnosed with GBS osteomyelitis between 2008 and 2017.
- Invasive cases were defined as an International Classification of Disease (ICD) code for osteomyelitis accompanied by a blood or bone culture positive for GBS within 2 weeks.
- Non-invasive cases were defined as an ICD code for osteomyelitis and a non-invasive culture positive for GBS from a concordant site within 2 weeks.
- We compared demographics, comorbid conditions, mortality for patients with invasive and non-invasive GBS osteomyelitis.
- For those with lower extremity GBS OM, we also assessed time to amputation.

Reference


1. Watkins LKF, McGee L, Schrag SJ, et al. Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016. *JAMA Intern Med.* February 2019. doi:10.1001/jamainternmed.2018.7269

Corresponding Author: federico.perez@va.gov

Patient Demographics & Comorbidities


	All (N = 1721)	Invasive Osteomyelitis (N = 1077)	Non-invasive osteomyelitis (N = 644)
Age (\pm SD)	63.2 \pm 10.1	63.2 \pm 10.3	63.3 \pm 9.8
Male	1691 (98%)	1058 (98%)	633 (98%)
Race			
White	1196 (69%)	756 (70%)	440 (68%)
Black	393 (23%)	231 (21%)	162 (25%)
Charlson Comorbidity Index	3.84 \pm 2.3	3.85 \pm 2.3	3.83 \pm 2.4
Co-Morbid Conditions			
Diabetes	1475 (86%)	929 (86%)	546 (85%)
Peripheral Vascular Disease	583 (34%)	348 (32%)	235 (36%)
Chronic Heart Disease	59 (3%)	33 (3%)	26 (4%)
Lower Extremity Osteomyelitis	877 (51%)	313 (29%)	564 (88%)

Mortality Among Patients with GBS Osteomyelitis



Funding: This work was supported in part by funds from Pfizer (FP, RJ) and by funds and facilities provided by the Cleveland Geriatric Research Education and Clinical Center (GRECC) and the Veterans Affairs (VA) Northeast Ohio Healthcare System. The findings and conclusions presented here are those of the authors, who are responsible for its content, and do not necessarily represent the views of the VA or of the United States Government.

Time to Amputation Among Patients with Lower Extremity GBS Osteomyelitis



Summary

- Among cases of GBS osteomyelitis, we identified 1077 patients with invasive and 692 patients with non-invasive osteomyelitis.
- Among those with lower extremity osteomyelitis, 11% of invasive cases had an amputation at 30 days while 2% of non-invasive cases had an amputation in the same time frame
- Mortality was similar among those with invasive and non-invasive GBS osteomyelitis over 1-year.

Conclusions

- Over 1/3 of the cases of osteomyelitis caused by GBS do not meet the case definition for invasive disease, suggesting that the rates of GBS osteomyelitis may be higher than previously reported.
- Whether diagnosed using invasive or non-invasive microbiological cultures, survival outcomes for people with GBS osteomyelitis were similar, suggesting that non-invasive GBS osteomyelitis is as clinically important as invasive GBS osteomyelitis.